Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583096 | 0.94 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3GPR119 | |
| SCHEMBL3579885 | 0.94 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3GPR119 | |
| SCHEMBL1504990 | 0.86 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3GPR119 | |
| SCHEMBL1504994 | 0.86 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3GPR119 | |
| SCHEMBL1504993 | 0.86 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3GPR119 | |
| SCHEMBL1526950 | 0.84 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3GPR119 | |
| SCHEMBL1526952 | 0.84 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3GPR119 | |
| SCHEMBL1526948 | 0.84 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3GPR119 | |
| SCHEMBL654477 | 0.82 | GPR119 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3GPR119 | |
| SCHEMBL3575303 | 0.80 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885CHRNB4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.